Radar, this project from [Mateusz Juszczyk] isn’t actually using radar. But thanks to the round LCD this desktop gadget does ...

Danish biotech Adcendo has accelerated its progression to a clinical-stage biotech by licensing an antibody-drug conjugate (ADC) from China's Multitude Therapeutics with potential in various forms of ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Invincible Season 5 cast grows as Jack Quaid joins as Gravitator, an autodidact engineer whose gravity gun has a documented ...

What do you get when you take 8,192 CH570 MCUs, put them on custom PCBs, and write firmware for this interconnected gaggle of ...

An antibody-drug conjugate (ADC) that GSK licensed from China's Hansoh Pharma in a $1.7 billion deal last year has been given breakthrough status by the FDA. The coveted designation for GSK5764227 ...

Peter Gratton, Ph.D., is a New Orleans-based editor and professor with over 20 years of experience in investing, economics, and public policy. Peter began covering markets at Multex (Reuters) and has ...

For your next book club meeting, liven up the conversation with these fun and thought-provoking book club questions For book lovers, there’s nothing more exciting than learning someone has read the ...

In the middle of a game night with friends, and looking for a simple and easy way to break the ice? Then a classic 21 Questions Game might be just what you are after—and we are here to help make it ...

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.